← Eichor
Study identifier: NCT07005128 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Condition: Small-cell Lung Cancer · Extensive Stage Small-cell Lung Cancer  ·  Sponsor: Amgen

PhasePhase 3
Planned participants330
Who can joinAll sexes, 18 Years to 99 Years
Healthy volunteersNo

About this study

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

This description comes directly from the study's public registry record.

Talk to the study team

Amgen Call Center  ·  866-572-6436  ·  medinfo@amgen.com

Always discuss trial participation with your own doctor first.

Locations (164)

Cancer and Blood Specialists of ArizonaCasa Grande, Arizona, United StatesRecruiting
City of Hope Cancer Center PhoenixGoodyear, Arizona, United StatesRecruiting
Genesis Cancer CenterHot Springs, Arkansas, United StatesRecruiting
Saint Bernards Medical CenterJonesboro, Arkansas, United StatesRecruiting
Providence Saint Jude Medical CenterFullerton, California, United StatesRecruiting
Translational Research in Oncology US Inc, Trio Central PharmacyLos Angeles, California, United StatesRecruiting
University of California Los AngelesSanta Monica, California, United StatesRecruiting
Presbyterian Intercommunity Hospital Health Whitter HospitalWhittier, California, United StatesRecruiting
Colorado West Healthcare System dba Grand Valley OncologyGrand Junction, Colorado, United StatesRecruiting
Hartford HealthCare Cancer Institute at The Hospital of Central ConnecticutNew Britain, Connecticut, United StatesRecruiting
Yale New Haven HospitalNew Haven, Connecticut, United StatesRecruiting
Eastern Connecticut Hematology and Oncology AssociatesNorwich, Connecticut, United StatesRecruiting

+ 152 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07005128